Pharmaceutical

AbbVie and Simcere Zaiming link to develop trispecific antibody

AbbVie and Simcere Zaiming have announced an option-to-license agreement for the development of an investigational drug candidate, SIM0500.

Jan 16, 2025 - 06:00
AbbVie and Simcere Zaiming link to develop trispecific antibody
AbbVie and Simcere Zaiming have announced an option-to-license agreement for the development of an investigational drug candidate, SIM0500.
Read the original article

Tags:

Previous Article

Insmed’s gene therapy poised to challenge DMD landscape after IND clearance

Next Article

JP Morgan 2025: Incyte expects period of ‘defining catalysts’

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

ARS Pharmaceuticals’ anaphylaxis nasal spray gains FDA approval

ARS Pharmaceuticals’ anaphylaxis nasal spray gains FDA ...

Aug 13, 2024

STAT+: Doctors’ lobby doubles down on the fight against expanding open access to research

STAT+: Doctors’ lobby doubles down on the fight against...

Jun 22, 2023

Bernie Sanders proposes subpoenas of CEOs of J&J, Merck on drug prices

Bernie Sanders proposes subpoenas of CEOs of J&J, Merck...

Jan 18, 2024